Literature DB >> 10940092

Effectiveness of amitriptyline in the prophylactic management of childhood headaches.

A D Hershey1, S W Powers, A L Bentti, T J Degrauw.   

Abstract

OBJECTIVE: To study the effectiveness of a standardized dose of amitriptyline, 1 mg/kg, for childhood headaches.
BACKGROUND: Amitriptyline has been shown to be effective for the prophylaxis of migraine in adults. Studies in children, however, have been quite limited. In adults, the suggested effective dose range is 10 to 150 mg. In children, a standardized dosage is often not used, resulting in a dosage range in clinical practice that often varies from a very low dose to a dose equivalent to that used in adults.
METHODS: Children with more than three headaches per month were treated with amitriptyline, slowly increasing the dose to 1 mg/kg per day. The frequency, severity, and duration of their headaches were initially evaluated and subsequently measured at each follow-up evaluation. Two hundred seventy-nine children had headaches occurring frequently enough to indicate prophylactic treatment. Of these children, 192 (68.8%) were treated with amitriptyline. The average age at presentation was 12.0 (+/- 3.0) years. The ratio of boys to girls was 1:1.74. The average frequency of headaches was 17.1 (+/- 10.1) days per month. The average severity was 6.84 (+/- 1.67) on a 10-point pain scale. The average duration was 11.5 (+/- 15.0) hours. The most frequent diagnoses using International Headache Society criteria were migraine (60.6%), migraine with aura (7.9%), and tension-type headache (10.4%). Of these children, 146 have been seen for at least one follow-up examination, occurring on average 67.3 (+/- 32.3) days after beginning prophylactic treatment.
RESULTS: A total of 84.2% of the children reported an overall perception of being better, while 11.6% reported being the same. The frequency of headaches improved to 9.2 (+/- 10.0) days per month. The average severity was reduced to 5.1 (+/- 2.1), and the average duration was reduced to 6.3 (+/- 11.1) hours. If daily or continuous headaches were excluded, the improvements were more marked. Minimal side effects were reported from these children and their families. Long-term evaluation (156 to 415 days) showed continued sustained improvement.
CONCLUSIONS: Amitriptyline is an effective prophylactic medication for children with frequent headaches. A standardized dosing regimen results in a significant number of children responding with minimal side effects. The children are able to tolerate this dosing scheme and demonstrate good adherence to a dosing schedule of once a day.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940092     DOI: 10.1046/j.1526-4610.2000.00085.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  41 in total

Review 1.  New Developments in the Prophylactic Drug Treatment of Pediatric Migraine: What Is New in 2017 and Where Does It Leave Us?

Authors:  Joanne Kacperski; Allyson Bazarsky
Journal:  Curr Pain Headache Rep       Date:  2017-08

Review 2.  Pharmacologic treatment of migraine.

Authors:  Marcy E Yonker
Journal:  Curr Pain Headache Rep       Date:  2006-10

Review 3.  Chronic daily headaches in children.

Authors:  Andrew D Hershey; Marielle A Kabbouche; Scott W Powers
Journal:  Curr Pain Headache Rep       Date:  2006-10

4.  Genomic expression patterns in medication overuse headaches.

Authors:  Andrew D Hershey; Danny Burdine; Marielle A Kabbouche; Scott W Powers
Journal:  Cephalalgia       Date:  2010-06-02       Impact factor: 6.292

5.  Chronic daily headache in the pediatric population.

Authors:  Andrew D Hershey; Jack Gladstein; Paul Winner
Journal:  Curr Treat Options Neurol       Date:  2007-01       Impact factor: 3.598

6.  Adherence to Biobehavioral Recommendations in Pediatric Migraine as Measured by Electronic Monitoring: The Adherence in Migraine (AIM) Study.

Authors:  Ashley M Kroon Van Diest; Rachelle Ramsey; Brandon Aylward; John W Kroner; Stephanie M Sullivan; Katie Nause; Janelle R Allen; Leigh A Chamberlin; Shalonda Slater; Kevin Hommel; Susan L LeCates; Marielle A Kabbouche; Hope L O'Brien; Joanne Kacperski; Andrew D Hershey; Scott W Powers
Journal:  Headache       Date:  2016-05-11       Impact factor: 5.887

Review 7.  Preventive drugs in childhood and adolescent migraine.

Authors:  Joanne Kacperski; Andrew D Hershey
Journal:  Curr Pain Headache Rep       Date:  2014-06

Review 8.  Treatment adherence in patients with headache: a systematic review.

Authors:  Rachelle R Ramsey; Jamie L Ryan; Andrew D Hershey; Scott W Powers; Brandon S Aylward; Kevin A Hommel
Journal:  Headache       Date:  2014-04-17       Impact factor: 5.887

9.  Patterns of Use of Peripheral Nerve Blocks and Trigger Point Injections for Pediatric Headache: Results of a Survey of the American Headache Society Pediatric and Adolescent Section.

Authors:  Christina L Szperka; Amy A Gelfand; Andrew D Hershey
Journal:  Headache       Date:  2016-10-12       Impact factor: 5.887

10.  Pharmacologic treatment of pediatric headaches: a meta-analysis.

Authors:  Khalil El-Chammas; Jill Keyes; Nathan Thompson; Jayanthi Vijayakumar; Dorothy Becher; Jeffrey L Jackson
Journal:  JAMA Pediatr       Date:  2013-03-01       Impact factor: 16.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.